Trade Report: The Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Receives $63.68 Average PT from Analysts

The Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Receives $63.68 Average PT from Analysts

Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) have earned an average recommendation of “Hold” from the thirteen analysts that are currently covering the firm. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $63.68.

Several research firms recently issued reports on AGIO. Canaccord Genuity raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the stock from $50.00 to $90.00 in a report on Monday, June 13th. Vetr raised shares of Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.42 price target for the company in a report on Monday, June 13th. BTIG Research began coverage on shares of Agios Pharmaceuticals in a report on Friday, August 19th. They set a “neutral” rating for the company. JPMorgan Chase & Co. raised shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $50.00 to $62.00 in a report on Monday, June 13th. Finally, Goldman Sachs Group Inc. restated a “neutral” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, August 10th.

Agios Pharmaceuticals (NASDAQ:AGIO) opened at 52.69 on Monday. The stock’s market capitalization is $2.00 billion. The firm has a 50-day moving average of $46.07 and a 200-day moving average of $46.30. Agios Pharmaceuticals has a 1-year low of $33.50 and a 1-year high of $81.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.99. The firm had revenue of $6.98 million for the quarter, compared to analysts’ expectations of $39.62 million. Agios Pharmaceuticals had a negative return on equity of 47.69% and a negative net margin of 320.33%. The company’s revenue for the quarter was down 47.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.85) earnings per share. Equities research analysts anticipate that Agios Pharmaceuticals will post ($5.04) EPS for the current year.

In other news, Director Lewis Clayton Jr. Cantley sold 627 shares of the stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $41.85, for a total value of $26,239.95. Following the sale, the director now directly owns 112,167 shares in the company, valued at $4,694,188.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Scott Biller sold 5,000 shares of the stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $55.00, for a total transaction of $275,000.00. Following the completion of the sale, the insider now owns 48,270 shares in the company, valued at $2,654,850. The disclosure for this sale can be found here. Company insiders own 10.55% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Flagship Ventures Fund 2007 L.P. acquired a new stake in Agios Pharmaceuticals during the first quarter valued at approximately $78,373,000. Capital Guardian Trust Co. raised its stake in Agios Pharmaceuticals by 57.6% in the second quarter. Capital Guardian Trust Co. now owns 668,100 shares of the biopharmaceutical company’s stock valued at $27,990,000 after buying an additional 244,178 shares in the last quarter. BlackRock Advisors LLC raised its stake in Agios Pharmaceuticals by 1,942.6% in the second quarter. BlackRock Advisors LLC now owns 253,023 shares of the biopharmaceutical company’s stock valued at $10,600,000 after buying an additional 240,636 shares in the last quarter. Fiera Capital Corp acquired a new stake in Agios Pharmaceuticals during the second quarter valued at approximately $9,707,000. Finally, BB Biotech AG raised its stake in Agios Pharmaceuticals by 9.4% in the second quarter. BB Biotech AG now owns 2,363,321 shares of the biopharmaceutical company’s stock valued at $99,011,000 after buying an additional 203,400 shares in the last quarter. Institutional investors and hedge funds own 81.59% of the company’s stock.

Related posts

Leave a Comment